|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TNKS1BP1 |
Gene summary for TNKS1BP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TNKS1BP1 | Gene ID | 85456 |
| Gene name | tankyrase 1 binding protein 1 | |
| Gene Alias | TAB182 | |
| Cytomap | 11q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0000723 | UniProtAcc | A0A024R542 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 85456 | TNKS1BP1 | LZE4T | Human | Esophagus | ESCC | 1.39e-07 | 2.66e-01 | 0.0811 |
| 85456 | TNKS1BP1 | LZE7T | Human | Esophagus | ESCC | 4.40e-03 | 8.63e-03 | 0.0667 |
| 85456 | TNKS1BP1 | LZE8T | Human | Esophagus | ESCC | 2.48e-06 | 2.75e-01 | 0.067 |
| 85456 | TNKS1BP1 | LZE20T | Human | Esophagus | ESCC | 1.81e-03 | 5.14e-02 | 0.0662 |
| 85456 | TNKS1BP1 | LZE24T | Human | Esophagus | ESCC | 2.51e-11 | 3.05e-01 | 0.0596 |
| 85456 | TNKS1BP1 | P1T-E | Human | Esophagus | ESCC | 6.12e-10 | 3.30e-01 | 0.0875 |
| 85456 | TNKS1BP1 | P2T-E | Human | Esophagus | ESCC | 1.14e-11 | 3.39e-01 | 0.1177 |
| 85456 | TNKS1BP1 | P4T-E | Human | Esophagus | ESCC | 1.70e-18 | 5.23e-01 | 0.1323 |
| 85456 | TNKS1BP1 | P5T-E | Human | Esophagus | ESCC | 1.57e-16 | 2.62e-01 | 0.1327 |
| 85456 | TNKS1BP1 | P8T-E | Human | Esophagus | ESCC | 6.94e-24 | 5.99e-01 | 0.0889 |
| 85456 | TNKS1BP1 | P9T-E | Human | Esophagus | ESCC | 5.33e-10 | 3.27e-01 | 0.1131 |
| 85456 | TNKS1BP1 | P10T-E | Human | Esophagus | ESCC | 1.71e-05 | 1.95e-02 | 0.116 |
| 85456 | TNKS1BP1 | P11T-E | Human | Esophagus | ESCC | 2.89e-03 | 6.15e-01 | 0.1426 |
| 85456 | TNKS1BP1 | P12T-E | Human | Esophagus | ESCC | 1.38e-16 | 4.87e-01 | 0.1122 |
| 85456 | TNKS1BP1 | P15T-E | Human | Esophagus | ESCC | 2.60e-08 | 2.54e-01 | 0.1149 |
| 85456 | TNKS1BP1 | P16T-E | Human | Esophagus | ESCC | 3.04e-05 | -7.29e-02 | 0.1153 |
| 85456 | TNKS1BP1 | P17T-E | Human | Esophagus | ESCC | 1.37e-10 | 3.93e-01 | 0.1278 |
| 85456 | TNKS1BP1 | P19T-E | Human | Esophagus | ESCC | 1.11e-03 | 2.78e-01 | 0.1662 |
| 85456 | TNKS1BP1 | P20T-E | Human | Esophagus | ESCC | 1.59e-10 | 1.17e-01 | 0.1124 |
| 85456 | TNKS1BP1 | P21T-E | Human | Esophagus | ESCC | 7.78e-21 | 4.60e-01 | 0.1617 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00322009 | Thyroid | PTC | telomere organization | 74/5968 | 159/18723 | 7.46e-05 | 6.43e-04 | 74 |
| GO:0071897110 | Thyroid | PTC | DNA biosynthetic process | 82/5968 | 180/18723 | 7.98e-05 | 6.81e-04 | 82 |
| GO:00319522 | Thyroid | PTC | regulation of protein autophosphorylation | 26/5968 | 43/18723 | 1.04e-04 | 8.42e-04 | 26 |
| GO:00063026 | Thyroid | PTC | double-strand break repair | 103/5968 | 251/18723 | 1.30e-03 | 7.40e-03 | 103 |
| GO:00319542 | Thyroid | PTC | positive regulation of protein autophosphorylation | 16/5968 | 27/18723 | 3.03e-03 | 1.49e-02 | 16 |
| GO:00331356 | Thyroid | PTC | regulation of peptidyl-serine phosphorylation | 62/5968 | 144/18723 | 3.05e-03 | 1.50e-02 | 62 |
| GO:0010800 | Thyroid | PTC | positive regulation of peptidyl-threonine phosphorylation | 17/5968 | 30/18723 | 4.31e-03 | 2.04e-02 | 17 |
| GO:00107991 | Thyroid | PTC | regulation of peptidyl-threonine phosphorylation | 23/5968 | 47/18723 | 1.09e-02 | 4.35e-02 | 23 |
| GO:00331384 | Thyroid | PTC | positive regulation of peptidyl-serine phosphorylation | 46/5968 | 108/18723 | 1.22e-02 | 4.78e-02 | 46 |
| GO:007121427 | Thyroid | ATC | cellular response to abiotic stimulus | 169/6293 | 331/18723 | 3.24e-11 | 1.08e-09 | 169 |
| GO:010400427 | Thyroid | ATC | cellular response to environmental stimulus | 169/6293 | 331/18723 | 3.24e-11 | 1.08e-09 | 169 |
| GO:007147825 | Thyroid | ATC | cellular response to radiation | 101/6293 | 186/18723 | 4.67e-09 | 1.04e-07 | 101 |
| GO:000072324 | Thyroid | ATC | telomere maintenance | 76/6293 | 131/18723 | 8.21e-09 | 1.75e-07 | 76 |
| GO:000931426 | Thyroid | ATC | response to radiation | 210/6293 | 456/18723 | 1.69e-08 | 3.39e-07 | 210 |
| GO:001810519 | Thyroid | ATC | peptidyl-serine phosphorylation | 153/6293 | 315/18723 | 2.28e-08 | 4.42e-07 | 153 |
| GO:0010212110 | Thyroid | ATC | response to ionizing radiation | 82/6293 | 148/18723 | 3.88e-08 | 7.15e-07 | 82 |
| GO:001820917 | Thyroid | ATC | peptidyl-serine modification | 161/6293 | 338/18723 | 5.23e-08 | 9.44e-07 | 161 |
| GO:007147927 | Thyroid | ATC | cellular response to ionizing radiation | 46/6293 | 72/18723 | 1.41e-07 | 2.30e-06 | 46 |
| GO:004677717 | Thyroid | ATC | protein autophosphorylation | 114/6293 | 227/18723 | 1.54e-07 | 2.49e-06 | 114 |
| GO:000700424 | Thyroid | ATC | telomere maintenance via telomerase | 44/6293 | 69/18723 | 2.84e-07 | 4.29e-06 | 44 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TNKS1BP1 | SNV | Missense_Mutation | c.1729N>T | p.Gly577Cys | p.G577C | Q9C0C2 | protein_coding | deleterious(0.04) | benign(0.035) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| TNKS1BP1 | SNV | Missense_Mutation | c.1642C>G | p.Pro548Ala | p.P548A | Q9C0C2 | protein_coding | tolerated(0.1) | benign(0.04) | TCGA-A2-A1FW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
| TNKS1BP1 | SNV | Missense_Mutation | novel | c.2095N>C | p.Ala699Pro | p.A699P | Q9C0C2 | protein_coding | deleterious(0.03) | possibly_damaging(0.469) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| TNKS1BP1 | SNV | Missense_Mutation | rs763983688 | c.196N>T | p.Arg66Trp | p.R66W | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A095-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| TNKS1BP1 | SNV | Missense_Mutation | c.88G>A | p.Glu30Lys | p.E30K | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TNKS1BP1 | SNV | Missense_Mutation | novel | c.540N>A | p.Asp180Glu | p.D180E | Q9C0C2 | protein_coding | deleterious(0.04) | benign(0.323) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TNKS1BP1 | SNV | Missense_Mutation | novel | c.41C>T | p.Ser14Phe | p.S14F | Q9C0C2 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-BH-A1EO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TNKS1BP1 | SNV | Missense_Mutation | rs774760397 | c.4129N>A | p.Gly1377Ser | p.G1377S | Q9C0C2 | protein_coding | tolerated(0.1) | benign(0.338) | TCGA-E9-A249-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| TNKS1BP1 | insertion | Frame_Shift_Ins | novel | c.5034_5035insAAAGTTTGCATTCTGGACCTTTGCCGTCTGCCTCCTAGGT | p.Gln1679LysfsTer69 | p.Q1679Kfs*69 | Q9C0C2 | protein_coding | TCGA-A7-A0D9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | ||
| TNKS1BP1 | insertion | Frame_Shift_Ins | novel | c.5149_5150insGGCACTCACCACCACACCTGGCTAATTTTTGTATTTTTAAT | p.Asn1717ArgfsTer20 | p.N1717Rfs*20 | Q9C0C2 | protein_coding | TCGA-A8-A07G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |